Trials / Completed
CompletedNCT00103948
The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
An 18-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 165 (actual)
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 25 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an 18-week, prospective, multi-center, randomized, double-blind, placebo-controlled, (1:1) parallel-group study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aricept |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-10-01
- Completion
- 2007-02-01
- First posted
- 2005-02-18
- Last updated
- 2015-11-03
Locations
4 sites across 3 countries: United States, Australia, Spain
Source: ClinicalTrials.gov record NCT00103948. Inclusion in this directory is not an endorsement.